| Literature DB >> 27228191 |
Hiroyuki Tsuchie1, Naohisa Miyakoshi1, Yuji Kasukawa1, Seietsu Senma2, Yuichiro Narita2, Seiya Miyamoto2, Yuji Hatakeyama2, Kana Sasaki2, Yoichi Shimada1.
Abstract
BACKGROUND: Multiple factors are involved in the development of atypical femoral fractures, and excessive curvature of the femur is thought to be one of them. However, the pathogenesis of femoral curvature is unknown. We evaluated the influence of factors related to bone metabolism and posture on the development of femoral curvature.Entities:
Keywords: 25-Hydroxyvitamin D; atypical femoral fracture; curved femur; osteomalacia; women
Mesh:
Substances:
Year: 2016 PMID: 27228191 PMCID: PMC4967262 DOI: 10.1080/03009734.2016.1185200
Source DB: PubMed Journal: Ups J Med Sci ISSN: 0300-9734 Impact factor: 2.384
Characteristics of study patients.
| Total number | 139 |
|---|---|
| Age (years) | 75.4 ± 10.0 |
| AP curvature (degrees) | 2.98 ± 3.32 |
| Lateral curvature (degrees) | 9.79 ± 2.48 |
| Laboratory examinations | |
| ALP (IU/L) | 270 ± 198 |
| Ca (mg/dL) | 9.15 ± 0.33 |
| IP (mg/dL) | 3.50 ± 0.43 |
| P1NP (μg/L) | 53.5 ± 33.5 |
| TRACP5b (mU/dL) | 280 ± 125 |
| Pentosidine (μg/mL) | 0.054 ± 0.030 |
| Homocysteine (nmol/mL) | 10.0 ± 5.9 |
| Intact PTH (pg/mL) | 44.0 ± 20.2 |
| 25(OH)D (ng/mL) | 22.6 ± 8.3 |
| 1,25(OH)2D (pg/mL) | 51.1 ± 18.6 |
| BMD (g/cm2) | |
| Lumbar spine | 0.722 ± 0.146 |
| Proximal femur | 0.486 ± 0.114 |
| Lumbar lordosis angle (degrees) | 23.1 ± 18.6 |
| Lumbo-sacral angle (degrees) | 25.6 ± 10.0 |
| Steroid usage: number | 5/139 |
| Average | 4.4 ± 3.4 |
| Vitamin D usage: number | 19/139 |
Values are expressed as number of patients, or mean ± SD with ranges.
1,25(OH)2D: 1,25-hydroxyvitamin D3; 25(OH)D: 25-hydroxyvitamin D; ALP: alkaline phosphatase; AP: antero-posterior; BMD: bone mineral density; Ca: calcium; IP: inorganic phosphorus; P1NP: intact procollagen I N-terminal propeptide; PTH: parathyroid hormone; TRACP5b: tartrate-resistant acid phosphatase 5b.
Univariate logistic regression analysis of lateral curvature.
| Variables | Non-curved | Curved | Standardized OR | 95% CI | |
|---|---|---|---|---|---|
| Number | 114 | 25 | |||
| Age (years) | 73.8 ± 9.8 | 82.7 ± 6.9 | 3.263 | 1.767–6.024 | <0.001 |
| Laboratory examinations | |||||
| ALP (IU/L) | 268 ± 212 | 279 ± 117 | 1.053 | 0.768–1.567 | 0.797 |
| Ca (mg/dL) | 9.18 ± 0.31 | 9 ± 0.39 | 0.563 | 0.352–0.9 | 0.017 |
| IP (mg/dL) | 3.52 ± 0.43 | 3.45 ± 0.44 | 0.848 | 0.542–1.325 | 0.468 |
| P1NP (μg/L) | 53.3 ± 33.5 | 54 ± 34.2 | 1.019 | 0.662–1.57 | 0.93 |
| TRACP5b (mU/dL) | 280 ± 123 | 280 ± 141 | 1 | 0.648–1.541 | 0.999 |
| Pentosidine (μg/mL) | 0.049 ± 0.02 | 0.077 ± 0.053 | 2.158 | 1.363–3.416 | 0.001 |
| Homocysteine (nmol/mL) | 9.0 ± 3.4 | 14.3 ± 11 | 2.606 | 1.479–4.592 | <0.001 |
| Intact PTH (pg/mL) | 41.6 ± 18 | 55.0 ± 25.9 | 1.792 | 1.197–2.682 | 0.005 |
| 25(OH)D (ng/mL) | 24 ± 8 | 16.4 ± 6.5 | 0.263 | 0.135–0.512 | <0.001 |
| 1,25(OH)2D (pg/mL) | 51.9 ± 19.1 | 47.4 ± 16.1 | 0.767 | 0.475–1.239 | 0.279 |
| BMD (g/cm2) | |||||
| Lumbar spine | 0.73 ± 0.144 | 0.683 ± 0.155 | 0.715 | 0.452–1.13 | 0.151 |
| Proximal femur | 0.503 ± 0.109 | 0.411 ± 0.106 | 0.433 | 0.269–0.697 | <0.001 |
| Lumbar lordosis angle (degrees) | 23.4 ± 19.1 | 21.4 ± 16.3 | 0.891 | 0.582–1.364 | 0.62 |
| Lumbo-sacral angle (degrees) | 25.8 ± 10.5 | 25.0 ± 7.5 | 0.93 | 0.604–1.43 | 0.74 |
| Steroid usage (mg) | 0.04 ± 0.26 | 0.72 ± 2.25 | 11.53 | 0.918–144.8 | 0.058 |
| Vitamin D usage (number) | 16 | 3 | 0.835 | 0.224–3.117 | 0.958 |
Values are expressed as number of patients, or mean ± SD with ranges.
1,25(OH)2D: 1,25-hydroxyvitamin D3; 25(OH)D: 25-hydroxyvitamin D; 95% CI: 95% confidence interval; ALP: alkaline phosphatase; BMD: bone mineral density; Ca: calcium; IP: inorganic phosphorus; OR: odds ratio; P1NP: intact procollagen I N-terminal propeptide; PTH: intact parathyroid hormone; TRACP5b: tartrate-resistant acid phosphatase 5b.
Univariate logistic regression analysis of anterior curvature.
| Variables | Non-curved | Curved | Standardized OR | 95% CI | |
|---|---|---|---|---|---|
| Number | 120 | 19 | |||
| Age (years) | 73.9 ± 9.7 | 84.9 ± 5.4 | 5.413 | 2.391–12.26 | <0.001 |
| Laboratory examinations | |||||
| ALP (IU/L) | 252 ± 135 | 381 ± 404 | 1.546 | 0.990–2.415 | 0.055 |
| Ca (mg/dL) | 9.18 ± 0.31 | 9 ± 0.43 | 0.573 | 0.342–0.962 | 0.036 |
| IP (mg/dL) | 3.52 ± 0.43 | 3.41 ± 0.44 | 0.754 | 0.451–1.258 | 0.279 |
| P1NP (μg/L) | 53.3 ± 33.1 | 54.6 ± 37.2 | 1.04 | 0.644–1.68 | 0.872 |
| TRACP5b (mU/dL) | 279 ± 120 | 285 ± 159 | 1.045 | 0.648–1.686 | 0.856 |
| Pentosidine (μg/mL) | 0.05 ± 0.02 | 0.082 ± 0.058 | 2.168 | 1.361–3.452 | 0.001 |
| Homocysteine (nmol/mL) | 9.6 ± 5.8 | 11.9 ± 6.4 | 1.317 | 0.895–1.938 | 0.163 |
| Intact PTH (pg/mL) | 42.2 ± 19.4 | 54.1 ± 23 | 1.633 | 1.064–2.506 | 0.025 |
| 25(OH)D (ng/mL) | 23.6 ± 8.1 | 16.8 ± 6.6 | 0.328 | 0.166–0.649 | 0.001 |
| 1,25(OH)2D (pg/mL) | 51.3 ± 19.1 | 49.3 ± 15.2 | 0.893 | 0.537–1.486 | 0.189 |
| BMD (g/cm2) | |||||
| Lumbar spine | 0.728 ± 0.149 | 0.679 ± 0.121 | 0.698 | 0.418–1.167 | 0.171 |
| Proximal femur | 0.497 ± 0.113 | 0.422 ± 0.097 | 0.517 | 0.313–0.851 | 0.01 |
| Lumbar lordosis angle (degrees) | 23.0 ± 18.2 | 23.2 ± 21.3 | 0.998 | 0.617–1.613 | 0.979 |
| Lumbo-sacral angle (degrees) | 25.7 ± 10.1 | 24.9 ± 9.6 | 0.921 | 0.57–1.488 | 0.737 |
| Steroid usage (mg) | 0.16 ± 1 | 0 | – | – | − |
| Vitamin D usage (number) | 17 | 2 | 0.713 | 0.151–3.367 | 0.943 |
Values are expressed as number of patients, or mean ± SD with ranges.
1,25(OH)2D: 1,25-hydroxyvitamin D3; 25(OH)D: 25-hydroxyvitamin D; 95% CI: 95% confidence interval; ALP: alkaline phosphatase; BMD: bone mineral density; Ca: calcium; IP: inorganic phosphorus; OR: odds ratio; P1NP: intact procollagen I N-terminal propeptide; PTH: intact parathyroid hormone; TRACP5b: tartrate-resistant acid phosphatase 5b.
Multivariate logistic regression analysis of lateral curvature.
| Variables | Standardized OR | 95% CI | |
|---|---|---|---|
| Age (years) | 2.312 | 1.142–4.681 | 0.02 |
| Laboratory examinations | |||
| Ca (mg/dL) | 0.649 | 0.344–1.223 | 0.187 |
| Pentosidine (μg/mL) | 1.445 | 0.833–2.509 | 0.193 |
| Homocysteine (nmol/mL) | 1.202 | 0.749–1.928 | 0.444 |
| Intact PTH (pg/mL) | 1.209 | 0.713–2.050 | 0.479 |
| 25(OH)D (ng/mL) | 0.776 | 0.426–1.414 | 0.004 |
| BMD (g/cm2) | |||
| Proximal femur | 0.776 | 0.426–1.414 | 0.404 |
Values are expressed as number of patients, or mean ± SD with ranges.
25(OH)D: 25-hydroxyvitamin D; 95% CI: 95% confidence interval; BMD: bone mineral density; Ca: calcium; OR: odds ratio; PTH: parathyroid hormone.
Multivariate logistic regression analysis of anterior curvature.
| Variables | Standardized OR | 95% CI | |
|---|---|---|---|
| Age (years) | 4.472 | 1.770–11.3 | 0.002 |
| Laboratory examinations | |||
| Ca (mg/dL) | 0.65 | 0.331–1.278 | 0.187 |
| Pentosidine (μg/mL) | 1.551 | 0.926–2.596 | 0.096 |
| Intact PTH (pg/mL) | 1.145 | 0.658–1.994 | 0.632 |
| 25(OH)D (ng/mL) | 0.385 | 0.165–0.898 | 0.027 |
| BMD (g/cm2) | |||
| Proximal femur | 1.111 | 0.564–2.19 | 0.763 |
Values are expressed as number of patients, or mean ± SD with ranges.
25(OH)D: 25-hydroxyvitamin D; 95% CI: 95% confidence interval; BMD: bone mineral density; Ca: calcium; OR: odds ratio; PTH: parathyroid hormone.